KDR and lung carcinoma: As VEGF and its receptors play an important role in tumor growth and metastasis, the use of anti-VEGF agents and VEGF-R inhibitors for the treatment of lung cancer is currently in development, and bevacizumab is the first anti-VEGF factor that has already been used in patients with lung cancer [110].